Goldman Sachs
FDMT icon

Goldman Sachs’s 4D Molecular Therapeutics FDMT Stock Holding History

Goldman Sachs’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.6M Buy
4,258,668
+53,230
+1% +$519K ﹤0.01% 1697
2026
Q1 		$39.2M Sell
4,205,438
-97,467
-2% -$848K ﹤0.01% 1776
2025
Q4 		$32.3M Buy
4,302,905
+174,489
+4% +$1.77M ﹤0.01% 1898
2025
Q3 		$35.9M Sell
4,128,416
-30,848
-0.7% -$184K ﹤0.01% 1696
2025
Q2 		$15.4M Sell
4,159,264
-9,130
-0.2% -$32.1K ﹤0.01% 2358
2025
Q1 		$13.5M Sell
4,168,394
-106,579
-2% -$502K ﹤0.01% 2409
2024
Q4 		$23.8M Buy
4,274,973
+683,943
+19% +$5.37M ﹤0.01% 1949
2024
Q3 		$38.8M Sell
3,591,030
-543,224
-13% -$9.01M 0.01% 1460
2024
Q2 		$86.8M Buy
4,134,254
+1,076,405
+35% +$27M 0.01% 870
2024
Q1 		$97.4M Buy
3,057,849
+2,241,506
+275% +$57.2M 0.02% 798
2023
Q4 		$16.5M Buy
816,343
+658,069
+416% +$8.66M ﹤0.01% 2084
2023
Q3 		$2.01M Sell
158,274
-35,991
-19% -$602K ﹤0.01% 3765
2023
Q2 		$3.51M Sell
194,265
-3,537
-2% -$65.1K ﹤0.01% 3414
2023
Q1 		$3.4M Buy
197,802
+79,458
+67% +$1.55M ﹤0.01% 3413
2022
Q4 		$2.63M Buy
118,344
+13,274
+13% +$205K ﹤0.01% 3714
2022
Q3 		$844K Sell
105,070
-28,493
-21% -$258K ﹤0.01% 4627
2022
Q2 		$932K Buy
133,563
+58,105
+77% +$565K ﹤0.01% 4671
2022
Q1 		$1.14M Buy
75,458
+41,963
+125% +$659K ﹤0.01% 4712
2021
Q4 		$735K Buy
33,495
+23,809
+246% +$584K ﹤0.01% 5090
2021
Q3 		$261K Buy
+9,686
New +$276K ﹤0.01% 5586
2021
Q2 		– Sell
-12,486
Closed -$542K – 6291
2021
Q1 		$542K Sell
12,486
-62,492
-83% -$2.77M ﹤0.01% 5056
2020
Q4 		$3.11M Buy
+74,978
New +$3.1M ﹤0.01% 3395

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's FDMT Position: Q2 2026 in Review

Goldman Sachs increased its 4D Molecular Therapeutics (FDMT) stake by 1.3% in Q2 2026, buying an estimated $519K and bringing the position to 4,258,668 shares worth $56.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1697.

Goldman Sachs first reported a position in FDMT in Q4 2020 and has held it in 22 quarters since. The position peaked at $97.4M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Goldman Sachs held 4,258,668 shares of 4D Molecular Therapeutics worth $56.6M as of Q2 2026.
  • Goldman Sachs bought 53,230 4D Molecular Therapeutics shares in Q2 2026, an estimated $519K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1697 holding.
  • Goldman Sachs first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Goldman Sachs's 4D Molecular Therapeutics position peaked at $97.4M in Q1 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.